Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in pediatric relapsed/refractory solid tumors or lymphoma
NCT03458728Phase 2Terminated
- Sponsor
- Bayer
- Start
- Apr 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in solid tumor, lymphoma, neuroblastoma, osteosarcoma (OS), rhabdomyosarcoma (RMS), sponsored by Bayer. Started Apr 2018; status: terminated.
02
Drugs
copanlisib
03
Conditions
solid tumorlymphomaneuroblastomaosteosarcoma (OS)rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT03458728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458728.